Effect of leflunomide on the peripheral nerves in rheumatoid arthritis

Internal Medicine Journal

Volumn 37, Issue 2, 2007, Pages 101-107

  Richards, B L ^a   Spies, J ^a   McGill, N ^a   Richards, G W ^a   Vaile, J ^a   Bleasel, J F ^a   Youssef, P P ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b QEII Building ^*  (Australia)

Author keywords

Arava; Leflunomide; Nerve conduction study; Paraesthesia; Peripheral nerve; Peripheral neuropathy; Rheumatoid arthritis

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; COLESTYRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

ACHILLES REFLEX; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRONEUROLOGY; FEMALE; HAND PARESTHESIA; HUMAN; LABORATORY TEST; MALE; NERVE CONDUCTION; NOCICEPTION; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOM; TOUCH;

AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; NEURITIS; PERIPHERAL NERVES; PROSPECTIVE STUDIES;

EID: 33846107389     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01266.x     Document Type: Article

References (25)

1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123-51.
2. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-41.
3. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritiswithleflunomide comparedwith placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
4. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
5. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multi-center trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66.
6. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.
7. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
8. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihalovic D, Dordevic J et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-603.
9. Weber W, Harnisch L. Leflunomide in rheumatoid arthritis: population pharmacokinetic analysis of phase III studies. Rheumatol Eur 1998; 27 Suppl. 2: 110.
10. Weaver A, Caldwell J, Olsen N, Cohen S, Strand V. Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum 1998; 41(Supplement): S131.
11. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001; 44: 1984-92.
12. Fleming A, Dodman S, Crown JM et al. Extra-articular manifestations in early rheumatoid disease. BMJ 1976; 1: 1241-3.
13. Hart FD, Golding JR. Rheumatoid neuropathy. BMJ 1960; 1: 1594-600.
14. Pallis CA, Scott JT. Peripheral neuropathy in rheumatoid arthritis. BMJ 1965; 1: 1141-7.
15. Trojaborg W. Electrodiagnosis in rheumatic disease. Clin Rheum Dis 1981; 7: 349-63.
16. Weller RO, Bruckner FE, Chamberlain MA. Rheumatoid neuropathy: a histological and electrophysiological study. J Neurol Neurosurg Psychiatry 1970; 33: 592-604.
17. Hill C, Pile K, Henderson D, Kirkham B. Neurological side effects in two patients receiving gold injections for rheumatoid arthritis. Br J Rheumatol 1995; 34: 989-90.
18. Olesen LL, Jensen TS. Prevention and management of drug-induced peripheral neuropathy. Drug Saf 1991; 6: 302-14.
19. Argov Z, Mastaglia FL. Drug-induced peripheral neuropathies. BMJ 1979; 1: 663-6.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
21. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA et al. Human diabetic endoneurial sorbital, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-96.
22. Carulli MT, Davies UM. Peripheral neuropathy: an unwanted effect of leflunomide? Rheumatology 2002; 41: 952-3.
23. TM (leflunomide) Product Monograph. Updated October 2005. Aventis Pharma. Available at http://www.sanofi-aventis.com.au/ live/au/en/layout.jsp?scat=46612D11-A05E-4C09-B5F1-A2109A4B08A8
24. Windebank A. Chemotherapeutic neuropathy. 1999; 12: 565-71.
25. Gaist D, Jeppesen U, Anderson M, Rodriguez G, Hallas J, Sindrup S et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-7.